

September 3, 2014

# **Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014**

## **CEO to Provide Update on the Recent Progress of the Company and Outlook for Chronic Pain Pipeline**

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"), today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.

Sergio Traversa, CEO of Relmada Therapeutics, will provide an update on the Company during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

### **Event: 16th Annual Rodman & Renshaw Global Investment Conference**

**Date: September 10, 2014**

**Time: 2:05 p.m. (Eastern Time)**

**Location: Kennedy II (4th Floor); the Palace Hotel in New York City**

If you are an institutional investor, and would like to attend the Relmada's presentation, please click on the following link ([www.rodman.com](http://www.rodman.com)) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Sergio Traversa.

The Relmada presentation will also be available via a live webcast. To access the webcast, please visit [www.rodman.com](http://www.rodman.com) or <http://www.wsj.com/webcast/rshg24/rlmd>. The webcast replay will remain available for 90 days following the live presentation.

### **About Relmada Therapeutics, Inc.**

Relmada Therapeutics is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

## **About Rodman & Renshaw Conferences, LLC –**

The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.

## **Forward-Looking Statements**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Visit our website at, [www.relmada.com](http://www.relmada.com)

SOURCE Relmada Therapeutics, Inc.